Tranquilizer Drugs Market: Rise in geriatric population are expected to drive the market

Tranquilizer Drugs Market: Overview

• Tranquilizers are drugs that reduce mental tension, relieve anxiety, and result in calm outlook without producing any marked degree of hypnosis or sedation. Tranquilizers are used extensively and occupy an important place in psychological disorders.  
• Atypical antipsychotics or second generation antipsychotics are a type of tranquilizers majorly used for the treatment of several psychiatric conditions such as bipolar disorder, schizophrenia. Moreover, they are utilized as an adjunct therapy in the treatment of major depressive disorder. Antipsychotics generally fall into two categories: typical and atypical.

Read Report Overview - https://www.transparencymarketresearch.com/tranquilizer-drugs-market.html

• The conventional or typical antipsychotics were first developed in the 1950s and were widely prescribed for the treatment of severe mental disorders. Thorazine (chlorpromazine) and Haldol (haloperidol) were the most commonly used typical antipsychotics. However, these drugs exhibited severe side effects, in response to which the pharmaceutical companies introduced atypical antipsychotics with reduced number of extrapyramidal side effects.
• Atypical antipsychotics were approved in the 1990s for treating various psychiatric disorders. These drugs proved to be more effective among treatment-resistant patients compared to the typical antipsychotics.
•  Introduction of drugs with greater efficacy and reduced side effects along with increasing prevalence of psychiatric disorders is likely to boost the tranquilizer drugs market in the near future

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75909

Key Drivers of Global Tranquilizer Drugs Market

• Increased investments in research & development for new product innovation, rise in psychological disorders, increasing stress due to changing lifestyle, and rise in geriatric population are expected to drive the global tranquilizer drugs market
• According to the WHO, the global geriatric population would reach around 2 billion (22% of global population) by 2050, which was around 524 million in 2010. The National Alliance on Mental Illness estimates that out of the 35 million population aged 65 years or older in the U.S., over six million persons suffer from depression.

Request for Analysis of COVID-19 Impact on Tranquilizer Drugs Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=75909

• At this stage of life, most people experience some type of anxiety disorders or depression. Thus, it is expected that increase in geriatric population would increase the number of patients suffering from psychiatric disorders. This, in turn, is anticipated to drive the tranquilizer drugs market.
• Rise in demand for tranquilizer drugs and market competitiveness has resulted in increasing investment in research & development for new product innovation. This is likely to drive the tranquilizer drugs market.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=75909

North America to Hold Major Share of Global Tranquilizer Drugs Market

• North America is projected to account for a prominent share of the global market during the forecast period. According to the estimates by Food and Drug Administration (FDA), over 60 million people receive prescriptions for tranquilizers every year. Mental illnesses are common in the U.S. with one in five adults living with some of kind of mental illness which accounted for 46.6 million people in 2017.
• Economic growth in India, China, Brazil, Mexico, and other countries in Asia and Latin America has improved the health care infrastructure and accessibility to innovative products and health care services. Moreover, rise in incidence of psychological disorders is expected to drive the tranquilizer drugs market.  

Pre Book Tranquilizer Drugs Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=75909&ltype=S

• Countries in Asia Pacific such as China, Japan, and Australia exhibit significant growth prospects in terms of rapid acceptance of novel molecules as well as the extensive use of generics. Moreover, this region has a large number of patients suffering from psychological distress, cancer, AIDS, and other chronic disorders, who experience episodes of depression and anxiety during their lifetime.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/